NR4A1 and breast cancer: Given the inapplicability of targeted anti-hormone receptor or anti-HER2 receptor therapies which have proven to be efficacious in other breast cancer subtypes and the more aggressive biologic behavior of TNBCs, our findings of a significant association between TNBC and OS survival align with previous reports, [21–23] particularly in this young patient cohort [23].